Andras Strassz
Chief Medical Officer Heidelberg Pharma
Dr. Strassz has been appointed Chief Medical Officer in March 2021. He has already joined the company in April 2020 as Senior Medical Officer to build up the clinical development function. He has strong experience in clinical development, including in oncology. Dr. Strassz joined Heidelberg Pharma from Affimed, where he served as Medical Director. Previously, he held positions in clinical development at Sandoz and Amgen, among others. He holds both an MD and MBA from the University of Pécs, Hungary.
Seminars
Tuesday 24th February 2026
Evaluating the Journey of Amanitin ADC Development Contextualised with HDP-101 Phase I/ II Clinical Data to Lay the Path for ADC Payload Differentiation
12:00 pm
- Laying out amanitin-based ADC as promising approach to overcoming drug resistance through differentiated payload mechanism of action
- Showcasing phase I/II dose escalation data of HDP-101: clinical performance and excellent safety and tolerability
- Explaining lessons learned across opportunities and hurdles of bringing a novel ADC payload to the clinic
